Publicaciones en las que colabora con Juan María González Lahoz (40)

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2011

  1. Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance

    Journal of Viral Hepatitis, Vol. 18, Núm. 1, pp. 11-16

2010

  1. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  2. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

2009

  1. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients

    HIV Medicine, Vol. 10, Núm. 1, pp. 53-59

  2. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

2008

  1. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 200-205

  2. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 3, pp. 699-704

2007

  1. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 11, pp. 1374-1376

2006

  1. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir

    AIDS Research and Human Retroviruses, Vol. 22, Núm. 4, pp. 333-337

  2. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 22, Núm. 12, pp. 1231-1235

2005

  1. Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain

    Journal of Clinical Virology, Vol. 33, Núm. 1, pp. 65-70

  2. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

    AIDS, Vol. 19, Núm. 6, pp. 569-575

2004

  1. Benefits in the lipid profile after substitution of abacavir for stavudine: A 48-week prospective study

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 12, pp. 1289-1292

  2. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 3, pp. 271-273

2003

  1. Avascular necrosis in HIV-infected patients receiving antiretroviral treatment: Study of seven cases

    HIV Clinical Trials, Vol. 4, Núm. 2, pp. 132-136

  2. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

    AIDS Patient Care and STDs, Vol. 17, Núm. 9, pp. 443-445

  3. First-line therapy and mitochondrial damage: Different nucleosides, different findings

    HIV Clinical Trials, Vol. 4, Núm. 1, pp. 11-19

  4. Gynecomastia in HIV-infected patients receiving antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 19, Núm. 9, pp. 739-741